VacZine Analytics  
MarketVIEW: meningococcal serogroup B vaccines

Published: January 2012

With the introduction of vaccines to prevent invasive meningococcal disease due serogroups ACWY, serogroup B now remains a major contributor to current disease burden, especially in Europe where it accounts for >50% of cases. Outer membrane vesicle (OMV) based vaccines have been used successfully to tackle clonal epidemics most recently in New Zealand and Normandy, however, these vaccines are strain specific and have limited utility on a global scale. Novartis and Pfizer vaccines are currently developing broader acting protein based vaccines, the former (4CmenB) is current undergoing registration in the EMA region.

This MarketVIEW product is a comprehensive commercial opportunity assessment which forecasts the potential of new menB vaccines to 2030. The product contains three forecast models (LO, BASE, HI) which examine different adoption scenarios across 40 countries. Detailed coverage of Novartis (4CMenB) and Pfizer (rLP2086) is included with a focus on development history to date and coverage of latest cost effectiveness issues. Other novel menB vaccine approaches are discussed.

This product is an ideal source of analysis for those wishing to assess the field of new meningococcal vaccines.


To order please contact your region account manager, buy "on-line" or order direct at:

VAMV031 Click here>>
Discounted option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?

© 2011 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains